Cost-effectiveness of golimumab versus infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- May 2014
has subject area
- 1117 Public Health and Health Services (FoR)
- 1402 Applied Economics (FoR)
- Health Policy & Services (Science Metrix)
published in
- Value in Health Journal